Name	SHARMILA	Customer ID	MED111029487
Age & Gender	27Y/F	Visit Date	Mar 22 2022 9:38AM
Ref Doctor	MediWheel		

## **X-RAY CHEST (PA VIEW)**

The heart size and configuration are within normal limits. The aortic arch is normal.

The lung fields show normal broncho-vascular markings.

Both the pulmonary hila are normal in size.

The costophrenic and cardiophrenic recesses and the domes of diaphragm are normal.


The bones and soft tissues of the chest wall show no abnormality.

### **IMPRESSION:**

• No significant abnormality demonstrated.

Reben Schene

DR.REKHA S.CHERIAN, DMRD.DNB.FRCR., CONSULTANT RADIOLOGIST



Type Ref. Dr 	: Mrs. SHARMILA : MED111029487 : 1802211243 : 27 Year(s) / Female : OP : MediWheel ation GROUPING AND Rh	Collection On Report On :		Biological Reference Interval
TYPINC (EDTA BI	<b>3</b> ood/Agglutination)			
	<b>RETATION:</b> Reconfirm the Blood gi	oup and Typing bef	fore blood transfusion	
	e Blood Count With - ESR			
Haemog (EDTA Bl	lobin ood/Spectrophotometry)	11.3	g/dL	12.5 - 16.0
	Cell Volume(PCV)/Haematocrit ood/Derived from Impedance)	35.1	%	37 - 47
RBC Co (EDTA Bl	unt ood/Impedance Variation)	4.90	mill/cu.mm	4.2 - 5.4
	orpuscular Volume(MCV) ood/Derived from Impedance)	71.7	fL	78 - 100
	orpuscular Haemoglobin(MCH) ood/Derived from Impedance)	23.1	pg	27 - 32
concentr	orpuscular Haemoglobin ration(MCHC) ood/Derived from Impedance)	32.2	g/dL	32 - 36
RDW-C (EDTA Bl	V ood/Derived from Impedance)	15.7	%	11.5 - 16.0
RDW-SI (EDTA Bl	D ood/Derived from Impedance)	39.40	fL	39 - 46
	ukocyte Count (TC) ood/Impedance Variation)	8050	cells/cu.mm	4000 - 11000
Neutroph (EDTA Blo <i>Cytometry</i> )	ood/Impedance Variation & Flow	54.4	%	40 - 75
Lympho (EDTA Bl <i>Cytometry</i> )	ood/Impedance Variation & Flow	38.6	%	20 - 45
Eosinopl (EDTA Bl Cytometry)	ood∕Impedance Variation & Flow	1.3	%	01 - 06
Monocyt (EDTA Bl Cytometry)	ood∕Impedance Variation & Flow	5.4	%	01 - 10
	S SIVAKUMAR Ph.D			Dr.E.Saravanan M.D.(Path) Consultant Pathologist Reg No : 73347
V	ERIFIED BY			

APPROVED BY

The results pertain to sample tested.

Page 1 of 7

Name	: Mrs. SHARMILA		
PID No.	: MED111029487	Register On : 22/03/2022 10:51 AM	$\mathbf{M}$
SID No.	: 1802211243	Collection On : 22/03/2022 11:07 AM	
Age / Sex	: 27 Year(s) / Female	Report On : 22/03/2022 6:46 PM	MEDALL
Туре	: OP	Printed On : 23/03/2022 10:26 AM	
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.3	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results a	re reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	4.38	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	3.11	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.10	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.43	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.02	10^3 / µl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	307	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	9.7	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.30	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	15	mm/hr	< 20
BUN / Creatinine Ratio	16.6		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	91.0	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

**INTERPRETATION:** Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine) (Urine - F/GOD - POD)

VERIFIED BY

Negative

Negative

an M.D(Path) Pathologist 73347 0

APPROVED BY

The results pertain to sample tested.

Dr S SIVAKUMAR Ph

Consultant Microbiologist

Page 2 of 7

	: Mrs. SHARMILA			
PID No.	: MED111029487	Register On : 2	22/03/2022 10:51 AM	C
SID No.	: 1802211243	Collection On :	22/03/2022 11:07 AM	
Age / Sex	: 27 Year(s) / Female	Report On :	22/03/2022 6:46 PM	MEDALL
Туре	: OP	Printed On :	23/03/2022 10:26 AM	
Ref. Dr	: MediWheel			
<u>Investig</u> a	ation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
	Postprandial (PPBS) PP/GOD-PAP)	94.0	mg/dL	70 - 140
Factors su Fasting bl	ood glucose level may be higher than	n Postprandial glucose,	because of physiological	and drugs can influence blood glucose level. surge in Postprandial Insulin secretion, Insulin cation during treatment for Diabetes.
Urine Gl (Urine - Pl	lucose(PP-2 hours)	Negative		Negative
	rea Nitrogen (BUN) rease UV / derived)	11.5	mg/dL	7.0 - 21
Creatinin	ne odified Jaffe)	0.69	mg/dL	0.6 - 1.1
(Serum/Ma				
<b>INTERP</b> ingestion	<b>RETATION:</b> Elevated Creatinine va of cooked meat, consuming Protein/	Creatine supplements,	Diabetic Ketoacidosis, pro	severe dehydration, Pre-eclampsia, increased olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine
INTERPI ingestion such as ce	<b>RETATION:</b> Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an	Creatine supplements,	Diabetic Ketoacidosis, pro	olonged fasting, renal dysfunction and drugs
INTERPI ingestion of such as ce etc. Uric Aci (Serum/En	<b>RETATION:</b> Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an	Creatine supplements, ngiotensin II receptor a	Diabetic Ketoacidosis, pro ntagonists, N-acetylcystein	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine
INTERPI ingestion of such as ce etc. Uric Aci (Serum/En Liver Fu Bilirubin	<b>RETATION:</b> Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an d <i>azymatic</i> ) <i>unction Test</i>	Creatine supplements, ngiotensin II receptor a	Diabetic Ketoacidosis, pro ntagonists, N-acetylcystein	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine
INTERPI ingestion of such as ce etc. Uric Aci (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>D</i> Bilirubir	<b>RETATION:</b> Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an d <i>azymatic</i> ) <i>unction Test</i> n(Total) <i>CA with ATCS</i> )	Creatine supplements, ngiotensin II receptor a 3.7	Diabetic Ketoacidosis, pr ntagonists,N-acetylcystein mg/dL	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0
INTERPI ingestion such as ce etc. Uric Aci (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>D</i> Bilirubir (Serum/ <i>D</i>	RETATION: Elevated Creatinine va of cooked meat, consuming Protein/ ofoxitin, cefazolin, ACE inhibitors, an id azymatic) unction Test n(Total) CA with ATCS) n(Direct) azotized Sulfanilic Acid) n(Indirect)	Creatine supplements, ngiotensin II receptor a 3.7 0.68	Diabetic Ketoacidosis, pro ntagonists,N-acetylcystein mg/dL mg/dL	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0 0.1 - 1.2
INTERPI ingestion of such as celetc. Uric Aci (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>Di</i> Bilirubir (Serum/ <i>Di</i> Bilirubir (Serum/ <i>De</i> SGOT/A Aminotr	RETATION: Elevated Creatinine va of cooked meat, consuming Protein/ ofoxitin, cefazolin, ACE inhibitors, an id azymatic) unction Test n(Total) CA with ATCS) n(Direct) azotized Sulfanilic Acid) n(Indirect)	Creatine supplements, ngiotensin II receptor a 3.7 0.68 0.18	Diabetic Ketoacidosis, pr ntagonists,N-acetylcystein mg/dL mg/dL mg/dL	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0 0.1 - 1.2 0.0 - 0.3
INTERPI ingestion of such as celet. Uric Aci (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>De</i> Bilirubir (Serum/ <i>De</i> SGOT/A Aminotr (Serum/ <i>Me</i> SGPT/A	RETATION: Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an d <i>uzymatic</i> ) <i>unction Test</i> n(Total) <i>CA with ATCS</i> ) n(Direct) <i>azotized Sulfanilic Acid</i> ) n(Indirect) <i>erived</i> ) AST (Aspartate ansferase)	Creatine supplements, ngiotensin II receptor a 3.7 0.68 0.18 0.50 24.0	Diabetic Ketoacidosis, pr ntagonists,N-acetylcystein mg/dL mg/dL mg/dL mg/dL	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0 0.1 - 1.2 0.0 - 0.3 0.1 - 1.0
INTERPI ingestion of such as celet. Uric Aci (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>Di</i> Bilirubir (Serum/ <i>Di</i> Bilirubir (Serum/ <i>Di</i> SGOT/A Aminotr (Serum/ <i>Ma</i> SGPT/A (Serum/ <i>Ma</i> (Serum/ <i>Ma</i>	RETATION: Elevated Creatinine va of cooked meat, consuming Protein/ foxitin, cefazolin, ACE inhibitors, an d azymatic) unction Test (Total) CA with ATCS) n(Direct) fazotized Sulfanilic Acid) n(Indirect) erived) AST (Aspartate ansferase) odified IFCC) LT (Alanine Aminotransferase)	Creatine supplements, ngiotensin II receptor a 3.7 0.68 0.18 0.50 24.0 27.5	Diabetic Ketoacidosis, pro ntagonists,N-acetylcystein mg/dL mg/dL mg/dL mg/dL U/L	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0 0.1 - 1.2 0.0 - 0.3 0.1 - 1.0 5 - 40
INTERPI ingestion of such as celet. Uric Acie (Serum/ <i>En</i> <i>Liver Fu</i> Bilirubir (Serum/ <i>De</i> Bilirubir (Serum/ <i>De</i> SGOT/A Aminotr (Serum/ <i>Me</i> SGPT/A (Serum/ <i>Me</i> SGPT/A (Serum/ <i>Me</i> SGOT(Ga (Serum/ <i>IF</i> Alkaline	RETATION: Elevated Creatinine va of cooked meat, consuming Protein/ of cooked meat, consuming Protein/ of cooked meat, consuming Protein/ of cooked meat, consuming Protein/ of cooked meat, consuming Protein/ account of the constant of the cooked account of the cooked of the cooked (account of the cooked of the cooked of the cooked of the cooked of the cooked of the cooked of the cooked of the cooked (account of the cooked of the coo	Creatine supplements, ngiotensin II receptor a 3.7 0.68 0.18 0.50 24.0 27.5	Diabetic Ketoacidosis, pr ntagonists,N-acetylcystein mg/dL mg/dL mg/dL mg/dL U/L U/L	olonged fasting, renal dysfunction and drugs ne, chemotherapeutic agent such as flucytosine 2.6 - 6.0 0.1 - 1.2 0.0 - 0.3 0.1 - 1.0 5 - 40 5 - 41





APPROVED BY

The results pertain to sample tested.

Page 3 of 7

Name	: Mrs. SHARMILA		
PID No.	: MED111029487	Register On : 22/03/2022 10:51	AM 🕐
SID No.	: 1802211243	Collection On : 22/03/2022 11:07	AM
Age / Sex	: 27 Year(s) / Female	<b>Report On</b> : 22/03/2022 6:46	PM MEDALL
Туре	: OP	Printed On : 23/03/2022 10:26	5 AM
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Albumin (Serum/Bromocresol green)	4.24	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	3.20	gm/dL	2.3 - 3.6
A : G RATIO (Serum/ <i>Derived</i> ) <i>Lipid Profile</i>	1.32		1.1 - 2.2
Cholesterol Total (Serum/CHOD-PAP with ATCS)	135.4	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	59.6	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

**INTERPRETATION:** The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the "usual" circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	41.2	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 50 - 59 High Risk: < 50
LDL Cholesterol (Serum/Calculated)	82.3	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	11.9	mg/dL	< 30



Dr.E.Saravanan M.D(Path) Consultant Pathologist Reg No : 73347

APPROVED BY

The results pertain to sample tested.

Page 4 of 7

Name	: Mrs. SHARMILA		
PID No.	: MED111029487	Register On : 22/03/2022 10:5	51 AM 🔼 🎦
SID No.	: 1802211243	Collection On : 22/03/2022 11:	
Age / Sex	: 27 Year(s) / Female	<b>Report On</b> : 22/03/2022 6:4	6 PM MEDALL
Туре	: OP	Printed On : 23/03/2022 10:	26 AM
Ref. Dr	: MediWheel		
<u>Investig</u> a	ation	<u>Observed</u> <u>Unit</u> <u>Value</u>	Biological Reference Interval
Non HD (Serum/Ca	L Cholesterol	<b>94.2</b> mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >=220
			<b>J B</b>

2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio	3.3		Optimal: < 3.3 Low Risk: 3.4 - 4.4
(Serum/Calculated)			Average Risk: 4.5 - 7.1
(beruils encounter)			Moderate Risk: 7.2 - 11.0
			High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio	1.4		Optimal: < 2.5
(TG/HDL)			Mild to moderate risk: 2.5 - 5.0
(Serum/Calculated)			High Risk: > 5.0
LDL/HDL Cholesterol Ratio	2		Optimal: 0.5 - 3.0
(Serum/Calculated)			Borderline: 3.1 - 6.0
			High Risk: > 6.0
<u>Glycosylated Haemoglobin (HbA1c)</u>			
HbA1C	6.1	%	Normal: 4.5 - 5.6
(Whole Blood/HPLC)			Prediabetes: 5.7 - 6.4
			Diabetic: >= 6.5
INTERPRETATION: If Diabetes - Good control :	6.1 - 7.0 % , Fair	control : 7.1 - 8.0 %, F	Poor control >= $8.1 \%$
Estimated Average Glucose	128.37	mg/dL	
6		-	

(Whole Blood)

#### **INTERPRETATION:** Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

#### <u>THYROID PROFILE / TFT</u>





**APPROVED BY** 

The results pertain to sample tested.

Page 5 of 7

Name	: Mrs. SHARMILA			
PID No.	: MED111029487	Register On	: 22/03/2022 10:51 AM	M
SID No.	: 1802211243	<b>Collection On</b>	: 22/03/2022 11:07 AM	
Age / Sex	: 27 Year(s) / Female	Report On	: 22/03/2022 6:46 PM	MEDALL
Туре	: OP	Printed On	: 23/03/2022 10:26 AM	
Ref. Dr	: MediWheel			
Investiga	ation	<u>Observed</u> <u>Value</u>	Unit	Biological Reference Interval
	odothyronine) - Total memiluminescent Immunometric Assay	0.73	ng/ml	0.7 - 2.04
Comment Total T3 v		on like pregnancy, o	lrugs, nephrosis etc. In such	cases, Free T3 is recommended as it is
	oxine) - Total vemiluminescent Immunometric Assay	5.23	μg/dl	4.2 - 12.0
<b>Commen</b> Total T4 v		on like pregnancy, o	łrugs, nephrosis etc. In such	cases, Free T4 is recommended as it is
	yroid Stimulating Hormone) memiluminescent Immunometric Assay	2.31	µIU/mL	0.35 - 5.50
Reference 1 st trimes 2 nd trime 3 rd trime (Indian TH <b>Commen</b> 1.TSH ref 2.TSH Le be of the o 3.Values&	erence range during pregnancy depen	n, reaching peak lev as influence on the	els between 2-4am and at a measured serum TSH conce	

#### Urine Analysis - Routine

COLOUR (Urine)	Pale Yellow	Yellow to Amber
APPEARANCE (Urine)	Clear	Clear
Protein (Urine/Protein error of indicator)	Negative	Negative
Glucose (Urine/GOD - POD)	Negative	Negative
Pus Cells (Urine/Automated – Flow cytometry)	<b>2 - 4</b> /hpf	NIL





APPROVED BY

The results pertain to sample tested.

Page 6 of 7

Name	: Mrs. SHARMILA		
PID No.	: MED111029487	Register On : 22/03/2022 10:51 AM	$\mathbf{C}$
SID No.	: 1802211243	Collection On : 22/03/2022 11:07 AM	
Age / Sex	: 27 Year(s) / Female	Report On : 22/03/2022 6:46 PM	MEDALL
Туре	: OP	Printed On : 23/03/2022 10:26 AM	
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Epithelial Cells (Urine/Automated – Flow cytometry)	1 - 2	/hpf	NIL
RBCs (Urine/Automated – Flow cytometry )	NIL	/hpf	NIL
Casts (Urine/Automated – Flow cytometry )	NIL	/hpf	NIL
Crystals (Urine/Automated – Flow cytometry )	NIL	/hpf	NIL
Others	NIL		

(Urine)

**INTERPRETATION:** Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.



D(Path) Pathologist 73347

APPROVED BY

-- End of Report --

The results pertain to sample tested.

Page 7 of 7

Name	SHARMILA	ID	MED111029487
Age & Gender	27Year(s)/FEMALE	Visit Date	3/22/2022 12:00:00 AM
Ref Doctor Name	MediWheel	•	

#### SONOGRAM REPORT - WHOLE ABDOMEN (TAS/TVS)

#### **Indication:** General check up

The liver is normal in size (11.7 cms) and shows uniform echotexture with no focal abnormality.

The gall bladder is normal sized and smooth walled and contains no calculus.

There is no intra or extra hepatic biliary ductal dilatation.

The pancreas shows a normal configuration and echotexture.

The pancreatic duct is normal.

The portal vein and IVC are normal.

The spleen is normal in size and measures 8.9 cms.

There is no free or loculated peritoneal fluid.

No para aortic lymphadenopathy is seen.

No abnormality is seen in the region of the adrenal glands.

The right kidney measures 11.3 x 3.9 cms.

The left kidney measures 10.9 x 4.3 cms.

Both kidneys are normal in size, shape and position. Cortical echoes are normal bilaterally.

There is no calculus or calyceal dilatation.

The ureters are not dilated.

Name	SHARMILA	ID	MED111029487
Age & Gender	27Year(s)/FEMALE	Visit Date	3/22/2022 12:00:00 AM
Ref Doctor Name	MediWheel		

The urinary bladder is smooth walled and uniformly transonic. There is no intravesical mass or calculus.

The uterus is retroverted, and measures 6.8 x 4.1 x 4.7 cms.

Myometrial echoes are homogeneous. No focal lesion is seen.

The endometrial thickness is 7.7 mm.

The right ovary measures 4.1 x 1.8 cms.

The left ovary measures 4.3 x 1.6 cms.

No significant mass or cyst is seen in the ovaries.

#### Small quantity of free fluid is seen in the pouch of Douglas.

Iliac fossae are normal. No mass or fluid collection is seen in the right iliac fossa. The appendix is not visualized.

#### Note:

An irregular moderately defined hypoechoic area measuring 2.4 x 1.5 cm is seen in the deep subcutaneous / muscle plane at the left lateral end of LSCS scar. No abnormal internal vascularity.

#### **IMPRESSION:**

\* An irregular moderately defined hypoechoic area in the deep subcutaneous / muscle plane at the

left lateral end of LSCS scar --- ? Scar Endometrosis.

--- Suggested Clinical and FNAC correlation.

ss

**DR. T. SANA** CONSULTANT SONOLOGIST



## Name: MRS. SHARMILA

# Age & Sex: 27 YEARS/MALE

Date : 22/03/2022

		Right Eye	Left Eye
DISTANT VISION	<u>Without Glasses</u> With Glass	6/12	6/12
NEAR VISION	<u>Without Glasses</u> With Glass	N6	N6
COLOUR VISION		NORMAL	
EXTERNAL EYE EXAMINATION		NORM	AL

**REMARKS:** 

Normel with glesses

.

Dr. Akila Ravikumar MBBS., M.Phil., P.G.Dip. Diabetology Regd. No. 46536 Consultant Family Physician & Diabetology at

You can also conveniently view the reports and trends through our App. Scan QR code to download the App.



Please produce bill copy at the time of collecting the reports. Request you to provide your mobile number or customer id during your subsequent visits.